Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
TGTX
#1254
TG Therapeutics, Inc.
34.5
6
USD
+2.28%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+2.28%
Changement Mensuel
+22.55%
Evolution sur 6 mois
+1.26%
Changement Annuel
-10.30%
Clôture Précédente
33.7
9
Open
34.5
6
Bid
Ask
Low
34.5
6
High
34.5
6
Volume
90
Marchés
Actions des Marchés US
Soins de Santé
TGTX
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
140.59 M
142.82 M
146.36 M
154.42 M
157.07 M
159.69 M
—
Valuation ratios
Enterprise value
6.78 B
2.49 B
1.67 B
2.65 B
4.8 B
4.93 B
23.07 B
Price to earnings ratio
—
—
-7.92
189.33
200.67
10.76
276.14
Price to sales ratio
—
—
562.55
10.83
14.67
7.81
48.04
Price to cash flow ratio
—
—
-8.89
-80.56
-119.11
-194.24
-480.03
Price to book ratio
—
—
26.73
15.77
21.7
7.43
25.69
Enterprise value to EBITDA ratio
-24.81
-7.04
-8.35
121.78
108.29
37.94
260.33
Profitability ratios
Return on assets %
-0.45
-0.92
-1.02
0.04
0.04
0.42
0.45
Return on equity %
-0.54
-1.47
-3.39
0.08
0.11
0.69
0.8
Return on invested capital %
-1 649.24
-2 168.43
-1 554.62
145.45
108.67
425.88
421.36
Gross margin %
100
100
100
93.95
88.3
83.66
336.54
Operating margin %
-180 K
-5 154.28
-6 924.2
8.83
12.74
20.01
76.2
EBITDA margin %
-179.28 K
-5 130.75
-6 839.5
8.92
12.76
20.02
76.24
Net margin %
-183.8 K
-5 204.08
-7 121.54
5.42
7.11
72.56
277.85
Liquidity ratios
Quick ratio
—
—
—
5.18
5.03
3.29
12.17
Current ratio
6.99
5.06
3.16
5.92
6.25
4.1
15.81
Inventory turnover
—
—
—
0.35
0.51
0.85
0.7
Asset turnover
0
0.01
0.01
0.89
0.73
0.75
0.78
Solvency ratios
Debt to assets ratio
0.03
0.21
0.43
0.34
0.44
0.24
1.23
Debt to equity ratio
0.04
0.33
1.42
0.69
1.14
0.39
2.8
Long term debt to total assets ratio
0.01
0.18
0.37
0.3
0.42
0.23
1.19
Long term debt to total equity ratio
0.01
0.28
1.21
0.62
1.1
0.38
2.7
Per share metrics
Operating cash flow per share
—
—
-1.3
-0.21
-0.25
-0.15
-0.15
EBIT per share
—
—
-1.42
0.14
0.26
0.76
0.76
EBITDA per share
—
—
-1.41
0.14
0.26
0.76
0.76
Total debt per share
—
—
0.61
0.75
1.58
1.57
6.27
Cash per share
—
—
1.29
1.46
1.94
1.24
5.76
Net current asset value per share
—
—
1.24
2.14
3.53
3.91
15.68
Tangible book value per share
—
—
0.43
1.08
1.39
4.01
10.94
Working capital per share
—
—
0.85
1.78
2.97
2.96
11.71
Book value per share
—
—
0.43
1.08
1.39
4.01
10.94
Nouvelles
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside (TGTX)
TG Therapeutics obtient une facilité de crédit de 750 millions de dollars avec Blue Owl
BRIUMVI démontre son efficacité chez les patients atteints de sclérose en plaques très active
BRIUMVI shows efficacy in highly active multiple sclerosis patients
TG Therapeutics présentera des données sur BRIUMVI lors d’un congrès de neurologie
TG Therapeutics to present BRIUMVI data at neurology meeting
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
Le BPA de TG a manqué les attentes de 0,23$, le CA a surpassé les prévisions
TG earnings missed by $0.23, revenue topped estimates
TG Therapeutics face au test des résultats alors que Briumvi accélère
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates